Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
- Written by Newsfile
FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson's Disease
Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the company held a successful Type B...